Therefore, this domain regulates blood lipids by affecting the redistribution of LDLR on the surface of hepatocytes, and now it is also the hot therapeutic target for hyperlipidemia treatment: the new drug pcsk-9 inhibitor can lower lipid [34]. Here, LDLR is linked to hyperlipidemia.